Literature DB >> 8748067

Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT.

W Kaschka1, H Feistel, D Ebert.   

Abstract

We compared a group of nine patients with panic disorder (DSM-III-R) and depression with a matched control group of nine dysthymic patients without a previous or actual history of panic attacks or anxiety with iomazenil SPECT (single photon emission computed tomography) to evaluate panic-related abnormalities of the benzodiazepine receptor complex. The panic group had a significant decrease (p < .05, U-tests) in the regional activity index (RAI) in the following regions after 2 h: lateral inferior temporal lobes, right and left, medial inferior temporal lobes, left, inferior frontal lobes, right and left. All other regions investigated were not significantly different. The findings may be due to either regional blood flow differences or benzodiazepine receptor effects. The hypothesis that the effects are due to altered blood flow is confirmed to some extent by similar findings in the scans acquired after 10 min. Only the hypoactivity in the left lateral temporal region seemed to be independent of reduced blood flow in panic disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8748067     DOI: 10.1016/0022-3956(95)00019-2

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  17 in total

Review 1.  Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.

Authors:  Thomas Dresler; Anne Guhn; Sara V Tupak; Ann-Christine Ehlis; Martin J Herrmann; Andreas J Fallgatter; Jürgen Deckert; Katharina Domschke
Journal:  J Neural Transm (Vienna)       Date:  2012-06-13       Impact factor: 3.575

2.  Acute pharmacological modulation of mGluR8 reduces measures of anxiety.

Authors:  Robert M Duvoisin; Tim Pfankuch; Julie M Wilson; Julie Grabell; Vijay Chhajlani; Dean G Brown; Edwin Johnson; Jacob Raber
Journal:  Behav Brain Res       Date:  2010-04-10       Impact factor: 3.332

Review 3.  Molecular pathways of anxiety revealed by knockout mice.

Authors:  S J Wood; M Toth
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

4.  Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges.

Authors:  Robert M Duvoisin; Laura Villasana; Matthew J Davis; Danny G Winder; Jacob Raber
Journal:  Behav Brain Res       Date:  2011-03-04       Impact factor: 3.332

5.  GABA(C) Receptors in the Lateral Amygdala: A Possible Novel Target for the Treatment of Fear and Anxiety Disorders?

Authors:  Catarina Cunha; Marie-H Monfils; Joseph E Ledoux
Journal:  Front Behav Neurosci       Date:  2010-03-12       Impact factor: 3.558

Review 6.  The neurocircuitry of fear, stress, and anxiety disorders.

Authors:  Lisa M Shin; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Dopamine and depression--striatal dopamine D2 receptor SPECT before and after antidepressant therapy.

Authors:  D Ebert; H Feistel; T Loew; A Pirner
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 8.  The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology.

Authors:  Elizabeth I Martin; Kerry J Ressler; Elisabeth Binder; Charles B Nemeroff
Journal:  Psychiatr Clin North Am       Date:  2009-09

9.  GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression.

Authors:  Irina Esterlis; Kelly P Cosgrove; Jeffery C Batis; Frederic Bois; Tracy A Kloczynski; Stephanie M Stiklus; Edward Perry; Gilles D Tamagnan; John P Seibyl; Robert Makuch; Suchitra Krishnan-Sarin; Stephanie O'Malley; Julie K Staley
Journal:  Synapse       Date:  2009-12       Impact factor: 2.562

10.  Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic disorder.

Authors:  Zaiyang Long; Carla Medlock; Mario Dzemidzic; Yong-Wook Shin; Andrew W Goddard; Ulrike Dydak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-04       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.